GENFIT has signed a licensing and collaboration agreement with Terns Pharmaceuticals to develop novel and combination therapies to treat liver disease.  Under the agreement, Terns will have the rights to develop and commercialize elafibranor, GENFIT’s pcompound, in Greater China, for the treatment of non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). Under the terms of the licensing agreement, GENFIT will receive an upfront payment from Terns of $35 million and will be ...